The Carbapenem-Based Antibiotics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Carbapenem-Based Antibiotics Market:
https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report
According to The Business Research Company’s Carbapenem-Based Antibiotics Global Market Report 2024, The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.43 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to epidemics and pandemics, rise in chronic diseases, healthcare infrastructure growth, rapid urbanization, natural disasters and health emergencies.
The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increased incidence of hospital-acquired infections, emergence of multi-drug resistant strains, growing aging population, rise in surgical procedures, proliferation of infectious diseases, changing demographics.. Major trends in the forecast period include supply chain resilience and security, alternative treatment development, shift towards outpatient settings, growing awareness on antimicrobial stewardship, precision medicine approaches.
The increasing incidence of bacterial infections is expected to propel the growth of the carbapenem-based antibiotics market going forward. Bacterial infections are infections caused by bacteria, microscopic organisms that can invade the body and cause a range of diseases and symptoms. Carbapenem-based antibiotics treat severe or multidrug-resistant bacterial infections, including those caused by gram-positive and gram-negative bacteria. For Instance, In November 2022, according to the report published by the UK Health Security Agency (UKHSA), an executive government agency of the Department of Health and Social Care, in England, the anticipated total number of antibiotic-resistant severe infections increased by 2.2% in 2021. Therefore, an increased incidence of bacterial infections drives the growth of the carbapenem-based antibiotics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp
The carbapenem-based antibiotics market covered in this report is segmented –
1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types
2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin and Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Product Innovations are the key trend gaining popularity in the carbapenem-based antibiotics market. Major companies operating in the carbapenem-based antibiotics market are innovating products to sustain their position in the market. For instance, in September 2021, BDR Pharmaceuticals International Pvt. Ltd. an India-based pharmaceutical company launched biapenem. Biapenem is administered to individuals suffering from lower respiratory infections, complex urinary tract infections, or intra-abdominal infections. Biapenem has demonstrated clinical and bacteriological efficacy that is comparable to imipenem/cilastatin in treating patients with these kinds of illnesses.
The carbapenem-based antibiotics market report table of contents includes:
1. Executive Summary
2. Carbapenem-Based Antibiotics Market Characteristics
3. Carbapenem-Based Antibiotics Market Trends And Strategies
4. Carbapenem-Based Antibiotics Market – Macro Economic Scenario
5. Global Carbapenem-Based Antibiotics Market Size and Growth
.
.
.
26. South America Carbapenem-Based Antibiotics Market
27. Brazil Carbapenem-Based Antibiotics Market
28. Middle East Carbapenem-Based Antibiotics Market
29. Africa Carbapenem-Based Antibiotics Market
30. Carbapenem-Based Antibiotics Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Merck & Co. Inc
- Saint-Gobain S.A
- Fresenius Kabi LLC
- GlaxoSmithKline PLC
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
